Literature DB >> 17682991

Evaluation of Mycobacterium tuberculosis--specific antibody responses in populations with different levels of exposure from Tanzania, Ethiopia, Brazil, and Denmark.

Soren T Hoff1, Markos Abebe, Pernille Ravn, Nyagosya Range, Wabyahe Malenganisho, Denise S Rodriques, Esper G Kallas, Christian Søborg, T Mark Doherty, Peter Andersen, Karin Weldingh.   

Abstract

BACKGROUND: New, simple, and better-performing diagnostic tools are needed for the diagnosis of tuberculosis (TB). Much effort has been invested in developing an antibody-based test for TB, but to date, no such test has performed with sufficient sensitivity and specificity. A key question remaining is the extent to which the disappointing performance of current tests is associated with a high background prevalence of latent TB.
METHODS: We compared Mycobacterium tuberculosis-specific ESAT-6 and CFP-10 antibody responses in a total of 565 human serum samples from M. tuberculosis-uninfected donors and donors with latent infection, as well as samples from patients with active TB. Our study included samples from 4 countries, representing environments with low, intermediate, and high TB incidences.
RESULTS: We demonstrated significant increases in antibody levels in latently infected contacts, compared with M. tuberculosis-uninfected individuals, and in patients with active TB disease, compared with latently infected contacts. Furthermore, we found a striking increase in the magnitude of the antibody responses in samples obtained from infected Ethiopian individuals (with and without disease), compared with Danish and Brazilian infected individuals; this was presumably the result of higher exposure levels.
CONCLUSIONS: Our study confirms the presence of ESAT-6 and CFP-10 antibodies in patients with TB, and we demonstrate that significant antibody responses are not restricted to active TB disease but can reflect latent infection, particularly in areas with high levels of exposure to M. tuberculosis. This finding is important for the understanding of the poor discriminatory power of current serodiagnostic tests in regions of endemicity, and it may have major implications on the future development of serologic tests.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17682991     DOI: 10.1086/520662

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  26 in total

1.  Antituberculosis IgG antibodies as a marker of active Mycobacterium tuberculosis disease.

Authors:  Ryan J Welch; Kathleen M Lawless; Christine M Litwin
Journal:  Clin Vaccine Immunol       Date:  2012-02-01

Review 2.  Performance of purified antigens for serodiagnosis of pulmonary tuberculosis: a meta-analysis.

Authors:  Karen R Steingart; Nandini Dendukuri; Megan Henry; Ian Schiller; Payam Nahid; Philip C Hopewell; Andrew Ramsay; Madhukar Pai; Suman Laal
Journal:  Clin Vaccine Immunol       Date:  2008-12-03

3.  Antibodies against immunodominant antigens of Mycobacterium tuberculosis in subjects with suspected tuberculosis in the United States compared by HIV status.

Authors:  Jacqueline M Achkar; Elisabeth Jenny-Avital; Xian Yu; Susanne Burger; Eric Leibert; Patrick W Bilder; Steven C Almo; Arturo Casadevall; Suman Laal
Journal:  Clin Vaccine Immunol       Date:  2010-01-13

4.  Evaluation of antigen-specific immunoglobulin g responses in pulmonary tuberculosis patients and contacts.

Authors:  Yun-Gyoung Hur; Ahreum Kim; Young Ae Kang; An Sik Kim; Dae Yeon Kim; Yeun Kim; Youngmi Kim; Hyeyoung Lee; Sang-Nae Cho
Journal:  J Clin Microbiol       Date:  2015-01-14       Impact factor: 5.948

5.  Construction of eukaryotic expression vectors encoding CFP-10 and ESAT-6 genes and their potential in lymphocyte proliferation.

Authors:  Azam Torabi; Mojtaba Tahmoorespour; Fatemeh Vahedi; Nader Mosavari; Mohammadreza Nassiri
Journal:  Rep Biochem Mol Biol       Date:  2013-10

Review 6.  Adjunctive tests for diagnosis of tuberculosis: serology, ELISPOT for site-specific lymphocytes, urinary lipoarabinomannan, string test, and fine needle aspiration.

Authors:  Jacqueline M Achkar; Stephen D Lawn; Mahomed-Yunus S Moosa; Colleen A Wright; Victoria O Kasprowicz
Journal:  J Infect Dis       Date:  2011-11-15       Impact factor: 5.226

7.  Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys.

Authors:  Steven G Reed; Rhea N Coler; Wilfried Dalemans; Wilifred Dalemans; Esterlina V Tan; Eduardo C DeLa Cruz; Randall J Basaraba; Ian M Orme; Yasir A W Skeiky; Mark R Alderson; Karen D Cowgill; Jean-Paul Prieels; Rodolfo M Abalos; Marie-Claude Dubois; Joe Cohen; Pascal Mettens; Yves Lobet
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-02       Impact factor: 11.205

8.  Rv1985c, a promising novel antigen for diagnosis of tuberculosis infection from BCG-vaccinated controls.

Authors:  Jiazhen Chen; Sen Wang; Ying Zhang; Xiaodi Su; Jing Wu; Lingyun Shao; Feifei Wang; Shu Zhang; Xinhua Weng; Honghai Wang; Wenhong Zhang
Journal:  BMC Infect Dis       Date:  2010-09-17       Impact factor: 3.090

Review 9.  A dynamic reinfection hypothesis of latent tuberculosis infection.

Authors:  P-J Cardona
Journal:  Infection       Date:  2009-03-23       Impact factor: 3.553

10.  Development of a proof of concept immunochromatographic lateral flow assay for point of care diagnosis of Mycobacterium tuberculosis.

Authors:  Liya Wassie; Markos Abebe; Abraham Aseffa; Kidist Bobosha; Martha Zewdie; Menberwork Chanyalew; Lawrence K Yamuah; Arantxa Cortés; Jose R González; Jose M Delgado; Ismail Ceyhan; Ida Rosenkrands; Karin Weldingh; Peter Andersen; Timothy Mark Doherty
Journal:  BMC Res Notes       Date:  2013-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.